MedChemExpress LLC (MCE)
  1. Companies
  2. MedChemExpress LLC (MCE)
  3. Products
  4. MedChemExpress - Model Cobolimab - ...

MedChemExpressModel Cobolimab -2022215-65-0

SHARE
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3].
Most popular related searches

MCE products for research use only. We do not sell to patients.

Cobolimab

MCE China:Cobolimab

Brand:MedChemExpress (MCE)

Cat. No.HY-P99827

CAS:2022215-65-0

Synonyms:TSR-022; GSK4069889

Purity:98.00%

Storage:Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping:Shipping with dry ice.

Description:Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC).

In Vitro:Cobolimab (0.0001-10 nM; 3 d) promotes TIM-3 internalization in a dose dependent manner in pre-activated T cells with an IC50 value of 0.4464 nM[3]. Cobolimab (20 µg/mL; 24 h) significantly increases CD8+ T cell content by inhibiting TIM-3[4].

Species:Humanized

Isotype:Human IgG4 kappa

Recommend Isotype Controls:Human IgG4 (S228P) kappa, Isotype Control

Hot selling product:Corticosterone  | Venetoclax  | Semaglutide  | Nigericin (sodium salt)  | ATP  | Eribulin  | Atezolizumab  | Cefiderocol  | Dexamethasone  | Trabectedin

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References:

[1]. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022.

[2]. Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219.  [Content Brief]

[3]. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236.  [Content Brief]

[4]. Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447.  [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
•   It has a professional experimental center and strict quality control and verification system;
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
•   The biological activity of the products has been verified by the experiments of customers in various countries;
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。